Monthly pill shows potential as pre-exposure prophylaxis HIV drug candidate

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., published in the open-access journal PLOS Biology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup